Medicus Pharma Ltd. (NASDAQ:MDCX – Free Report) – Equities research analysts at Brookline Capital Management boosted their FY2025 earnings per share estimates for shares of Medicus Pharma in a report released on Tuesday, April 8th. Brookline Capital Management analyst K. Raja now forecasts that the company will earn ($0.88) per share for the year, up from their previous estimate of ($1.53). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Management also issued estimates for Medicus Pharma’s FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at $0.44 EPS.
Medicus Pharma (NASDAQ:MDCX – Get Free Report) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14.
Get Our Latest Analysis on MDCX
Medicus Pharma Price Performance
Shares of Medicus Pharma stock opened at $3.58 on Friday. The stock has a 50-day moving average price of $3.44. Medicus Pharma has a fifty-two week low of $1.80 and a fifty-two week high of $6.00.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma accounts for 1.3% of Interchange Capital Partners LLC’s portfolio, making the stock its 15th largest position. Interchange Capital Partners LLC owned about 13.43% of Medicus Pharma at the end of the most recent quarter.
Medicus Pharma Company Profile
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Read More
- Five stocks we like better than Medicus Pharma
- Learn Technical Analysis Skills to Master the Stock Market
- JPMorgan is a Buy, if You Can Handle The Volatility
- Stock Market Upgrades: What Are They?
- United States Steel’s Crash: An Unmissable Buying Opportunity
- How Technical Indicators Can Help You Find Oversold Stocks
- Rocket Lab Stock: Weathering the Storm, Time for a Comeback?
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.